{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T08:17:09Z","timestamp":1768292229869,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre de Recherche du CHUS"},{"name":"Foundation of the Stars"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fragile X syndrome (FXS) is the most prevalent inherited cause of intellectual disabilities and autism spectrum disorders. FXS result from the loss of expression of the FMRP protein, an RNA-binding protein that regulates the expression of key synaptic effectors. FXS is also characterized by a wide array of behavioural, cognitive and metabolic impairments. The severity and penetrance of those comorbidities are extremely variable, meaning that a considerable phenotypic heterogeneity is found among fragile X individuals. Unfortunately, clinicians currently have no tools at their disposal to assay a patient prognosis upon diagnosis. Since the absence of FMRP was repeatedly associated with an aberrant protein synthesis, we decided to study the nascent proteome in order to screen for potential proteomic biomarkers of FXS. We used a BONCAT (Biorthogonal Non-canonical Amino Acids Tagging) method coupled to label-free mass spectrometry to purify and quantify nascent proteins of peripheral blood mononuclear cells (PBMCs) from 7 fragile X male patients and 7 age-matched controls. The proteomic analysis identified several proteins which were either up or downregulated in PBMCs from FXS individuals. Eleven of those proteins were considered as potential biomarkers, of which 5 were further validated by Western blot. The gene ontology enrichment analysis highlighted molecular pathways that may contribute to FXS physiopathology. Our results suggest that the nascent proteome of PBMCs is well suited for the discovery of FXS biomarkers.<\/jats:p>","DOI":"10.1038\/s41598-021-94027-5","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T10:11:30Z","timestamp":1627294290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A new strategy to uncover fragile X proteomic biomarkers using the nascent proteome of peripheral blood mononuclear cells (PBMCs)"],"prefix":"10.1038","volume":"11","author":[{"given":"Olivier","family":"Dionne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"94027_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13052-017-0355-y","volume":"43","author":"C Ciaccio","year":"2017","unstructured":"Ciaccio, C. et al. Fragile X syndrome: A review of clinical and molecular diagnoses. Ital. J. Pediatr. 43, 39 (2017).","journal-title":"Ital. J. Pediatr."},{"key":"94027_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1542\/peds.2013-4301","volume":"134","author":"SA Kidd","year":"2014","unstructured":"Kidd, S. A. et al. Fragile X syndrome: A review of associated medical problems. Pediatrics 134, 995\u20131005 (2014).","journal-title":"Pediatrics"},{"key":"94027_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0174301","volume":"12","author":"A \u00c7aku","year":"2017","unstructured":"\u00c7aku, A. et al. New insights of altered lipid profile in fragile X syndrome. PLoS\u00a0One 12, e0174301 (2017).","journal-title":"PLoS\u00a0One"},{"key":"94027_CR4","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(91)90125-I","volume":"66","author":"M Pieretti","year":"1991","unstructured":"Pieretti, M. et al. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817\u2013822 (1991).","journal-title":"Cell"},{"key":"94027_CR5","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","volume":"65","author":"AJMH Verkerk","year":"1991","unstructured":"Verkerk, A. J. M. H. et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905\u2013914 (1991).","journal-title":"Cell"},{"key":"94027_CR6","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1399-0004.2011.01798.x","volume":"82","author":"M Lessard","year":"2012","unstructured":"Lessard, M., Chouiali, A., Drouin, R., S\u00e9bire, G. & Corbin, F. Quantitative measurement of FMRP in blood platelets as a new screening test for fragile X syndrome. Clin. Genet. 82, 472\u2013477 (2012).","journal-title":"Clin. Genet."},{"key":"94027_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226811","volume":"14","author":"K Kim","year":"2019","unstructured":"Kim, K. et al. Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS\u00a0One 14, e0226811 (2019).","journal-title":"PLoS\u00a0One"},{"key":"94027_CR8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3390\/brainsci10100694","volume":"10","author":"DB Budimirovic","year":"2020","unstructured":"Budimirovic, D. B. et al. A genotype-phenotype study of high-resolution FMR1 nucleic acid and protein analyses in fragile X patients with neurobehavioral assessments. Brain Sci. 10, 694 (2020).","journal-title":"Brain Sci."},{"key":"94027_CR9","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/brainsci9050096","volume":"9","author":"M Zafarullah","year":"2019","unstructured":"Zafarullah, M. & Tassone, F. Molecular biomarkers in fragile X syndrome. Brain Sci. 9, 96 (2019).","journal-title":"Brain Sci."},{"key":"94027_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/brainsci9030059","volume":"9","author":"R Pal","year":"2019","unstructured":"Pal, R. & Bhattacharya, A. Modelling protein synthesis as a biomarker in fragile X syndrome patient-derived cells. Brain Sci. 9, 59 (2019).","journal-title":"Brain Sci."},{"key":"94027_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3109\/1354750X.2016.1160289","volume":"21","author":"D Pellerin","year":"2016","unstructured":"Pellerin, D. et al. Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: Potential of platelet\u2019s signaling cascades as new outcome measures in clinical trials. Biomarkers 21, 497\u2013508 (2016).","journal-title":"Biomarkers"},{"key":"94027_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1002\/ajmg.a.36023","volume":"161","author":"M Dziembowska","year":"2013","unstructured":"Dziembowska, M. et al. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. Am. J. Med. Genet. A 161, 1897\u20131903 (2013).","journal-title":"Am. J. Med. Genet. A"},{"key":"94027_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00213-013-3022-z","volume":"228","author":"CA Erickson","year":"2013","unstructured":"Erickson, C. A. et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: An open-label study in youth with fragile X syndrome. Psychopharmacology 228, 75\u201384 (2013).","journal-title":"Psychopharmacology"},{"key":"94027_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jpsychires.2014.07.011","volume":"59","author":"CA Erickson","year":"2014","unstructured":"Erickson, C. A. et al. Impact of acamprosate on plasma amyloid-\u03b2 precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J. Psychiatr. Res. 59, 220\u2013228 (2014).","journal-title":"J. Psychiatr. Res."},{"key":"94027_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.braindev.2017.01.012","volume":"39","author":"RR AlOlaby","year":"2017","unstructured":"AlOlaby, R. R. et al. Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome. Brain Dev. 39, 483\u2013492 (2017).","journal-title":"Brain Dev."},{"key":"94027_CR16","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3390\/brainsci10060361","volume":"10","author":"M Jasoliya","year":"2020","unstructured":"Jasoliya, M. et al. Blood-based biomarkers predictive of metformin target engagement in fragile X syndrome. Brain Sci. 10, 361 (2020).","journal-title":"Brain Sci."},{"key":"94027_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s11689-020-09315-4","volume":"12","author":"AJ Thurman","year":"2020","unstructured":"Thurman, A. J. et al. Controlled trial of lovastatin combined with an open-label treatment of a parent-implemented language intervention in youth with fragile X syndrome. J. Neurodev. Disord. 12, 12 (2020).","journal-title":"J. Neurodev. Disord."},{"key":"94027_CR18","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20178126","volume":"14","author":"C Ludwig","year":"2018","unstructured":"Ludwig, C. et al. Data-independent acquisition-based SWATH-MS for quantitative proteomics: A tutorial. Mol. Syst. Biol. 14, e8126 (2018).","journal-title":"Mol. Syst. Biol."},{"key":"94027_CR19","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/nprot.2006.273","volume":"1","author":"B Cox","year":"2006","unstructured":"Cox, B. & Emili, A. Tissue subcellular fractionation and protein extraction for use in mass-spectrometry-based proteomics. Nat. Protoc. 1, 1872\u20131878 (2006).","journal-title":"Nat. Protoc."},{"key":"94027_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-021-00432-0","author":"JD Richter","year":"2021","unstructured":"Richter, J. D. & Zhao, X. The molecular biology of FMRP: New insights into fragile X syndrome. Nat. Rev. Neurosci. https:\/\/doi.org\/10.1038\/s41583-021-00432-0 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"94027_CR21","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s12035-018-1122-9","volume":"56","author":"TC Dockendorff","year":"2019","unstructured":"Dockendorff, T. C. & Labrador, M. The fragile X protein and genome function. Mol. Neurobiol. 56, 711\u2013721 (2019).","journal-title":"Mol. Neurobiol."},{"key":"94027_CR22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/biology10050433","volume":"10","author":"O Dionne","year":"2021","unstructured":"Dionne, O. & Corbin, F. An, \u201cOmic\u201d overview of fragile X syndrome. Biology 10, 433 (2021).","journal-title":"Biology"},{"key":"94027_CR23","doi-asserted-by":"crossref","unstructured":"Bagni, C. & Klann, E. Molecular functions of the mammalian fragile X mental retardation protein: Insights into mental retardation and synaptic plasticity. The Autisms: Molecules to Model Systems 126\u2013146 (2012).","DOI":"10.1093\/med\/9780199744312.003.0008"},{"key":"94027_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/fmolb.2018.00113","volume":"5","author":"T Maurin","year":"2018","unstructured":"Maurin, T. & Bardoni, B. Fragile X mental retardation protein: To be or not to be a translational enhancer. Front. Mol. Biosci. 5, 113 (2018).","journal-title":"Front. Mol. Biosci."},{"key":"94027_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","volume":"146","author":"JC Darnell","year":"2011","unstructured":"Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247\u2013261 (2011).","journal-title":"Cell"},{"key":"94027_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/00004583-200303000-00019","volume":"42","author":"PJ Lombroso","year":"2003","unstructured":"Lombroso, P. J. Genetics of childhood disorders: XLVIII. Learning and memory, Part 1: Fragile X syndrome update. J. Am. Acad. Child Adolesc. Psychiatry 42, 372\u2013375 (2003).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"94027_CR27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.tins.2004.04.009","volume":"27","author":"MF Bear","year":"2004","unstructured":"Bear, M. F., Huber, K. M. & Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370\u2013377 (2004).","journal-title":"Trends Neurosci."},{"key":"94027_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0251367","volume":"16","author":"O Dionne","year":"2021","unstructured":"Dionne, O., Lortie, A., Gagnon, F. & Corbin, F. Rates of protein synthesis are reduced in peripheral blood mononuclear cells (PBMCs) from fragile X individuals. PLoS\u00a0One 16, e0251367 (2021).","journal-title":"PLoS\u00a0One"},{"key":"94027_CR29","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/ajmg.b.30272","volume":"141B","author":"PF Sullivan","year":"2006","unstructured":"Sullivan, P. F., Fan, C. & Perou, C. M. Evaluating the comparability of gene expression in blood and brain. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B, 261\u2013268 (2006).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"94027_CR30","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.0601637103","volume":"103","author":"DC Dieterich","year":"2006","unstructured":"Dieterich, D. C., Link, A. J., Graumann, J., Tirrell, D. A. & Schuman, E. M. Selective identification of newly synthesized proteins in mammalian cells using bioorthogonal noncanonical amino acid tagging (BONCAT). Proc. Natl. Acad. Sci. 103, 9482\u20139487 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"94027_CR31","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.2401","volume":"10","author":"AJM Howden","year":"2013","unstructured":"Howden, A. J. M. et al. QuaNCAT: Quantitating proteome dynamics in primary cells. Nat. Methods 10, 343\u2013346 (2013).","journal-title":"Nat. Methods"},{"key":"94027_CR32","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1161\/STROKEAHA.113.004576","volume":"45","author":"F Bian","year":"2014","unstructured":"Bian, F. et al. Nascent proteomes in peripheral blood mononuclear cells as a novel source for biomarker discovery in human stroke. Stroke 45, 1177\u20131179 (2014).","journal-title":"Stroke"},{"key":"94027_CR33","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1021\/acs.jproteome.0c00299","volume":"19","author":"HL Bowling","year":"2020","unstructured":"Bowling, H. L. et al. Optimization of protocols for detection of de novo protein synthesis in whole blood samples via azide-alkyne cycloaddition. J. Proteome Res. 19, 3856\u20133866 (2020).","journal-title":"J. Proteome Res."},{"key":"94027_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jim.2012.06.003","volume":"382","author":"K-Y Choi","year":"2012","unstructured":"Choi, K.-Y., Lippert, D. N. D., Ezzatti, P. & Mookherjee, N. Defining TNF-\u03b1 and IL-1\u03b2 induced nascent proteins: Combining bio-orthogonal non-canonical amino acid tagging and proteomics. J. Immunol. Methods 382, 189\u2013195 (2012).","journal-title":"J. Immunol. Methods"},{"key":"94027_CR35","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41467-019-09553-8","volume":"10","author":"H Bowling","year":"2019","unstructured":"Bowling, H. et al. Altered steady state and activity-dependent de novo protein expression in fragile X syndrome. Nat. Commun. 10, 1710 (2019).","journal-title":"Nat. Commun."},{"key":"94027_CR36","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/nprot.2016.136","volume":"11","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11, 2301\u20132319 (2016).","journal-title":"Nat. Protoc."},{"key":"94027_CR37","doi-asserted-by":"publisher","first-page":"D506","DOI":"10.1093\/nar\/gky1049","volume":"47","author":"The UniProt Consortium","year":"2019","unstructured":"The UniProt Consortium. UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506\u2013D515 (2019).","journal-title":"Nucleic Acids Res."},{"key":"94027_CR38","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","volume":"13","author":"J Cox","year":"2014","unstructured":"Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell Proteomics 13, 2513\u20132526 (2014).","journal-title":"Mol. Cell Proteomics"},{"key":"94027_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"94027_CR40","unstructured":"R Core Team. R: A language and environment for statistical computing. (R Foundation for Statistical Computing) (2020)."},{"key":"94027_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-98141-3","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2009","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2009). https:\/\/doi.org\/10.1007\/978-0-387-98141-3."},{"key":"94027_CR42","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res. 46, D649\u2013D655 (2018).","journal-title":"Nucleic Acids Res."},{"key":"94027_CR43","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","volume":"47","author":"TGO Resource","year":"2019","unstructured":"Resource, T. G. O. 20 years and still GOing strong. Nucleic Acids Res. 47, D330\u2013D338 (2019).","journal-title":"Nucleic Acids Res."},{"key":"94027_CR44","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41596-019-0128-8","volume":"14","author":"H Mi","year":"2019","unstructured":"Mi, H. et al. Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). Nat. Protoc. 14, 703\u2013721 (2019).","journal-title":"Nat. Protoc."},{"key":"94027_CR45","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1755-8794-8-S4-S2","volume":"8","author":"A Handen","year":"2015","unstructured":"Handen, A. & Ganapthiraju, M. K. LENS: Web-based lens for enrichment and network studies of human proteins. BMC Med. Genomics 8, S2 (2015).","journal-title":"BMC Med. Genomics"},{"key":"94027_CR46","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12859-017-1934-z","volume":"18","author":"CT Rueden","year":"2017","unstructured":"Rueden, C. T. et al. Image J2: ImageJ for the next generation of scientific image data. BMC Bioinform. 18, 529 (2017).","journal-title":"BMC Bioinform."},{"key":"94027_CR47","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature11737","volume":"492","author":"M Ascano","year":"2012","unstructured":"Ascano, M. et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492, 382\u2013386 (2012).","journal-title":"Nature"},{"key":"94027_CR48","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1093\/nar\/gky267","volume":"46","author":"T Maurin","year":"2018","unstructured":"Maurin, T. et al. HITS-CLIP in various brain areas reveals new targets and new modalities of RNA binding by fragile X mental retardation protein. Nucleic Acids Res. 46, 6344\u20136355 (2018).","journal-title":"Nucleic Acids Res."},{"key":"94027_CR49","doi-asserted-by":"publisher","first-page":"31791","DOI":"10.1074\/jbc.M805971200","volume":"283","author":"G Mayer","year":"2008","unstructured":"Mayer, G., Poirier, S. & Seidah, N. G. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem. 283, 31791\u201331801 (2008).","journal-title":"J. Biol. Chem."},{"key":"94027_CR50","doi-asserted-by":"publisher","first-page":"17732","DOI":"10.1074\/jbc.M113.541094","volume":"289","author":"K Ly","year":"2014","unstructured":"Ly, K. et al. Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9. J. Biol. Chem. 289, 17732\u201317746 (2014).","journal-title":"J. Biol. Chem."},{"key":"94027_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041865","volume":"7","author":"NG Seidah","year":"2012","unstructured":"Seidah, N. G. et al. Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. PLoS\u00a0One 7, e41865 (2012).","journal-title":"PLoS\u00a0One"},{"key":"94027_CR52","doi-asserted-by":"crossref","unstructured":"Ben Djoudi Ouadda, A. et al. Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor). ATVB 39, 1996\u20132013 (2019).","DOI":"10.1161\/ATVBAHA.119.313247"},{"key":"94027_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0371-y","author":"J Jin","year":"2019","unstructured":"Jin, J. et al. Ahnak scaffolds p11\/Anxa2 complex and L-type voltage-gated calcium channel and modulates depressive behavior. Mol. Psychiatry https:\/\/doi.org\/10.1038\/s41380-019-0371-y (2019).","journal-title":"Mol. Psychiatry"},{"key":"94027_CR54","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","volume":"74","author":"A Michalon","year":"2012","unstructured":"Michalon, A. et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49\u201356 (2012).","journal-title":"Neuron"},{"key":"94027_CR55","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/ajmg.b.30765","volume":"147B","author":"N Weng","year":"2008","unstructured":"Weng, N., Weiler, I. J., Sumis, A., Berry-Kravis, E. & Greenough, W. T. Early-phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 1253\u20131257 (2008).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"94027_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.neuron.2012.07.022","volume":"76","author":"A Bhattacharya","year":"2012","unstructured":"Bhattacharya, A. et al. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76, 325\u2013337 (2012).","journal-title":"Neuron"},{"key":"94027_CR57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1471-4159.2012.07722.x","volume":"121","author":"X Wang","year":"2012","unstructured":"Wang, X. et al. Activation of the extracellular signal-regulated kinase pathway contributes to the behavioral deficit of fragile X-syndrome. J. Neurochem. 121, 672\u2013679 (2012).","journal-title":"J. Neurochem."},{"key":"94027_CR58","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3389\/fncel.2019.00105","volume":"13","author":"L Shen","year":"2019","unstructured":"Shen, L. et al. Proteomics study of peripheral blood mononuclear cells (PBMCs) in autistic children. Front. Cell. Neurosci. 13, 105 (2019).","journal-title":"Front. Cell. Neurosci."},{"key":"94027_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrm1789","volume":"7","author":"KR Legate","year":"2006","unstructured":"Legate, K. R., Monta\u00f1ez, E., Kudlacek, O. & F\u00fcssler, R. ILK, PINCH and parvin: The tIPP of integrin signalling. Nat. Rev. Mol. Cell Biol. 7, 20\u201331 (2006).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"94027_CR60","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.biocel.2009.10.015","volume":"42","author":"JE Lai-Cheong","year":"2010","unstructured":"Lai-Cheong, J. E., Parsons, M. & McGrath, J. A. The role of kindlins in cell biology and relevance to human disease. Int. J. Biochem. Cell Biol. 42, 595\u2013603 (2010).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"94027_CR61","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1101\/gad.1758709","volume":"23","author":"KR Legate","year":"2009","unstructured":"Legate, K. R., Wickstr\u00f6m, S. A. & F\u00e4ssler, R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 23, 397\u2013418 (2009).","journal-title":"Genes Dev."},{"key":"94027_CR62","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.cytogfr.2005.03.003","volume":"16","author":"JL Walker","year":"2005","unstructured":"Walker, J. L., Fournier, A. K. & Assoian, R. K. Regulation of growth factor signaling and cell cycle progression by cell adhesion and adhesion-dependent changes in cellular tension. Cytokine Growth Factor Rev. 16, 395\u2013405 (2005).","journal-title":"Cytokine Growth Factor Rev."},{"key":"94027_CR63","doi-asserted-by":"publisher","first-page":"26329","DOI":"10.1074\/jbc.271.42.26329","volume":"271","author":"H-C Chen","year":"1996","unstructured":"Chen, H.-C., Appeddu, P. A., Isoda, H. & Guan, J.-L. Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase. J. Biol. Chem. 271, 26329\u201326334 (1996).","journal-title":"J. Biol. Chem."},{"key":"94027_CR64","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ncb1094","volume":"6","author":"DJ Webb","year":"2004","unstructured":"Webb, D. J. et al. FAK\u2013Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat. Cell Biol. 6, 154\u2013161 (2004).","journal-title":"Nat. Cell Biol."},{"key":"94027_CR65","doi-asserted-by":"publisher","first-page":"18671","DOI":"10.1074\/jbc.M300879200","volume":"278","author":"R Pankov","year":"2003","unstructured":"Pankov, R. et al. Specific beta1 integrin site selectively regulates Akt\/protein kinase B signaling via local activation of protein phosphatase 2A. J. Biol. Chem. 278, 18671\u201318681 (2003).","journal-title":"J. Biol. Chem."},{"key":"94027_CR66","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1128\/MCB.22.5.1352-1359.2002","volume":"22","author":"J Ivaska","year":"2002","unstructured":"Ivaska, J. et al. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol. Cell. Biol. 22, 1352\u20131359 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"94027_CR67","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1002\/humu.22699","volume":"35","author":"D Kumari","year":"2014","unstructured":"Kumari, D. et al. Identification of fragile X syndrome specific molecular markers in human fibroblasts: A useful model to test the efficacy of therapeutic drugs. Hum. Mutat. 35, 1485\u20131494 (2014).","journal-title":"Hum. Mutat."},{"key":"94027_CR68","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2119\/molmed.2011.00363","volume":"18","author":"C Gross","year":"2012","unstructured":"Gross, C. & Bassell, G. J. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110\u03b2-selective inhibitor. Mol. Med. 18, 336\u2013345 (2012).","journal-title":"Mol. Med."},{"key":"94027_CR69","doi-asserted-by":"publisher","first-page":"10624","DOI":"10.1523\/JNEUROSCI.0402-10.2010","volume":"30","author":"C Gross","year":"2010","unstructured":"Gross, C. et al. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30, 10624\u201310638 (2010).","journal-title":"J. Neurosci."},{"key":"94027_CR70","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.neures.2011.02.006","volume":"70","author":"AB McGeachie","year":"2011","unstructured":"McGeachie, A. B., Cingolani, L. A. & Goda, Y. A stabilising influence: Integrins in regulation of synaptic plasticity. Neurosci. Res. 70, 24\u201329 (2011).","journal-title":"Neurosci. Res."},{"key":"94027_CR71","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1523\/JNEUROSCI.4091-05.2006","volume":"26","author":"Y Shi","year":"2006","unstructured":"Shi, Y. & Ethell, I. M. Integrins control dendritic spine plasticity in hippocampal neurons through NMDA receptor and Ca2+\/calmodulin-dependent protein kinase II-mediated actin reorganization. J. Neurosci. 26, 1813\u20131822 (2006).","journal-title":"J. Neurosci."},{"key":"94027_CR72","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1523\/JNEUROSCI.4110-05.2006","volume":"26","author":"C-S Chan","year":"2006","unstructured":"Chan, C.-S. et al. \u03b21-Integrins are required for hippocampal AMPA receptor-dependent synaptic transmission, synaptic plasticity, and working memory. J. Neurosci. 26, 223\u2013232 (2006).","journal-title":"J. Neurosci."},{"key":"94027_CR73","doi-asserted-by":"publisher","first-page":"9867","DOI":"10.1523\/JNEUROSCI.1162-14.2014","volume":"34","author":"H Sidhu","year":"2014","unstructured":"Sidhu, H., Dansie, L. E., Hickmott, P. W., Ethell, D. W. & Ethell, I. M. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J. Neurosci. 34, 9867\u20139879 (2014).","journal-title":"J. Neurosci."},{"key":"94027_CR74","doi-asserted-by":"publisher","first-page":"18234","DOI":"10.1523\/JNEUROSCI.2207-13.2013","volume":"33","author":"A Janusz","year":"2013","unstructured":"Janusz, A. et al. The fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses. J. Neurosci. 33, 18234\u201318241 (2013).","journal-title":"J. Neurosci."},{"key":"94027_CR75","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jmg.2008.061796","volume":"46","author":"TV Bilousova","year":"2009","unstructured":"Bilousova, T. V. et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46, 94\u2013102 (2009).","journal-title":"J. Med. Genet."},{"key":"94027_CR76","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrn.2016.138","volume":"17","author":"YK Park","year":"2016","unstructured":"Park, Y. K. & Goda, Y. Integrins in synapse regulation. Nat. Rev. Neurosci. 17, 745\u2013756 (2016).","journal-title":"Nat. Rev. Neurosci."},{"key":"94027_CR77","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fnana.2018.00040","volume":"12","author":"M Ferrer-Ferrer","year":"2018","unstructured":"Ferrer-Ferrer, M. & Dityatev, A. Shaping synapses by the neural extracellular matrix. Front. Neuroanat. 12, 40 (2018).","journal-title":"Front. Neuroanat."},{"key":"94027_CR78","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.neuron.2008.04.011","volume":"58","author":"LA Cingolani","year":"2008","unstructured":"Cingolani, L. A. et al. Activity-dependent regulation of synaptic AMPA receptor composition and abundance by beta3 integrins. Neuron 58, 749\u2013762 (2008).","journal-title":"Neuron"},{"key":"94027_CR79","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-6606-6-15","volume":"6","author":"MS Sidorov","year":"2013","unstructured":"Sidorov, M. S., Auerbach, B. D. & Bear, M. F. Fragile X mental retardation protein and synaptic plasticity. Mol. Brain 6, 15 (2013).","journal-title":"Mol. Brain"},{"key":"94027_CR80","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1471-4159.2009.06314.x","volume":"111","author":"Y Shang","year":"2009","unstructured":"Shang, Y. et al. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J. Neurochem. 111, 635\u2013646 (2009).","journal-title":"J. Neurochem."},{"key":"94027_CR81","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/cercor\/bht237","volume":"25","author":"CA Bostrom","year":"2015","unstructured":"Bostrom, C. A. et al. Rescue of NMDAR-dependent synaptic plasticity in Fmr1 knock-out mice. Cereb Cortex 25, 271\u2013279 (2015).","journal-title":"Cereb Cortex"},{"key":"94027_CR82","doi-asserted-by":"publisher","first-page":"11591","DOI":"10.1073\/pnas.1002262107","volume":"107","author":"A Suvrathan","year":"2010","unstructured":"Suvrathan, A., Hoeffer, C. A., Wong, H., Klann, E. & Chattarji, S. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. U.S.A. 107, 11591\u201311596 (2010).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"94027_CR83","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.celrep.2014.10.064","volume":"9","author":"CG Gkogkas","year":"2014","unstructured":"Gkogkas, C. G. et al. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes. Cell Rep. 9, 1742\u20131755 (2014).","journal-title":"Cell Rep."},{"key":"94027_CR84","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0092-8674(02)00971-6","volume":"110","author":"RO Hynes","year":"2002","unstructured":"Hynes, R. O. Integrins: Bidirectional, allosteric signaling machines. Cell 110, 673\u2013687 (2002).","journal-title":"Cell"},{"key":"94027_CR85","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/09537104.2017.1317733","volume":"29","author":"D Pellerin","year":"2018","unstructured":"Pellerin, D., Lortie, A. & Corbin, F. Platelets as a surrogate disease model of neurodevelopmental disorders: Insights from fragile X syndrome. Platelets 29, 113\u2013124 (2018).","journal-title":"Platelets"},{"key":"94027_CR86","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fnmol.2018.00041","volume":"11","author":"R Dahlhaus","year":"2018","unstructured":"Dahlhaus, R. Of men and mice: Modeling the fragile X syndrome. Front. Mol. Neurosci. 11, 41 (2018).","journal-title":"Front. Mol. Neurosci."},{"key":"94027_CR87","doi-asserted-by":"publisher","first-page":"M111.011429","DOI":"10.1074\/mcp.M111.011429","volume":"11","author":"F-M Boisvert","year":"2012","unstructured":"Boisvert, F.-M. et al. A quantitative spatial proteomics analysis of proteome turnover in human cells. Mol. Cell. Proteomics 11, M111.011429 (2012).","journal-title":"Mol. Cell. Proteomics"},{"key":"94027_CR88","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1021\/pr5006982","volume":"13","author":"G Zhang","year":"2014","unstructured":"Zhang, G. et al. In-depth quantitative proteomic analysis of de novo protein synthesis induced by brain-derived neurotrophic factor. J. Proteome Res. 13, 5707\u20135714 (2014).","journal-title":"J. Proteome Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94027-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94027-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T11:44:25Z","timestamp":1670067865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-94027-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["94027"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-94027-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15148"}}